Bristol-Myers To Buy Orum's Cancer Treatment Program
Clinical-stage private biotechnology company Orum Therapeutics, advised by Sterne Kessler Goldstein & Fox PLLC and Skadden, announced Monday that global pharmaceutical company Bristol-Myers Squibb has agreed to buy its program that...To view the full article, register now.
Already a subscriber? Click here to view full article